LCG
HAE icon

Lisanti Capital Growth’s Haemonetics HAE Stock Holding History

Lisanti Capital Growth’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-78,425
Closed -$7.03M – 149
2023
Q3 		$7.03M Buy
+78,425
New +$7M 1.11% 33
2023
Q2 		– Sell
-57,275
Closed -$4.74M – 155
2023
Q1 		$4.74M Sell
57,275
-40,245
-41% -$3.26M 0.66% 65
2022
Q4 		$7.67M Buy
+97,520
New +$7.84M 1.05% 38
2019
Q4 		– Sell
-53,385
Closed -$6.73M – 122
2019
Q3 		$6.73M Buy
+53,385
New +$6.78M 2.2% 9
2019
Q1 		– Sell
-46,765
Closed -$4.68M – 120
2018
Q4 		$4.68M Buy
46,765
+22,645
+94% +$2.38M 1.89% 11
2018
Q3 		$2.76M Buy
+24,120
New +$2.5M 0.96% 47

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lisanti Capital Growth's HAE Position: Q4 2023 in Review

Lisanti Capital Growth sold out of Haemonetics (HAE) in Q4 2023, closing a stake of 78,425 shares — an estimated $7.03M sold.

Lisanti Capital Growth first reported a position in HAE in Q3 2018 and held it in 6 quarters. The position peaked at $7.67M in Q4 2022. 295 funds tracked by Wall St. Rank hold HAE as of Q4 2023.

  • Lisanti Capital Growth reported no remaining Haemonetics position as of Q4 2023 after selling out during the quarter.
  • Lisanti Capital Growth sold 78,425 Haemonetics shares in Q4 2023, an estimated $7.03M.
  • Lisanti Capital Growth first reported a position in Haemonetics in Q3 2018 and held it in 6 quarters.
  • Lisanti Capital Growth's Haemonetics position peaked at $7.67M in Q4 2022.
  • 295 funds tracked by Wall St. Rank held Haemonetics as of Q4 2023.

Based on Lisanti Capital Growth's 13F filing for Q4 2023, filed 6 Feb 2024.